ISIN:CH0038389992

EQS-News: Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.00 per share

Retrieved on: 
Mercoledì, Aprile 10, 2024
CHF, BB Biotech, Annual general meeting, Holding company

Media release of March 21, 2024

Key Points: 
  • Media release of March 21, 2024
    All proposals of BB Biotech AG's Board of Directors were approved by BB Biotech AG's shareholders at its Annual General Meeting held today.
  • Shareholders voted in favor of the proposal to pay out a dividend of CHF 2.00 gross per share.
  • Payment will be made on March 27, 2024, the record date is March 26, 2024 and the ex-dividend date is March 25, 2024.
  • The Board of Directors thanks him for his valuable contribution and personal commitment to BB Biotech over the past 13 years.

EQS-News: Investor interest returns – dividend yield remains high for 2024

Retrieved on: 
Mercoledì, Febbraio 14, 2024
Acquisition, Annual general meeting, RSV, USD, Cystic fibrosis, Ionis, FDA, Pain, Patient, Policy, BB Biotech, Alnylam Pharmaceuticals, Depression, Pharmaceutical industry

Release as at February 14, 2024

Key Points: 
  • Release as at February 14, 2024
    After a difficult 2023 stock market year, above all due to higher interest rates, the capital markets are now once again looking at biotech companies with interest.
  • The prospect of falling interest rates has led to a rethink.
  • A dividend of this magnitude is exceptional not just in the Swiss equity market, but also in an international comparison.
  • Experts are anticipating similarly high approval figures for 2024 too.

EQS-News: Anlegerinteresse kehrt zurück – Unverändert hohe Dividendenrendite im 2024

Retrieved on: 
Mercoledì, Febbraio 14, 2024
Zins, Gefallen, Gros, Anleger, Pipeline, Verbindung, Kapitalmarkt, Unternehmen, Beschaffung, Betriebsnotwendiges Vermögen, Sektor, Marke (Recht), Substanzwert, BB, USD, Performance, CHF, Aktie, Lauf, Buchwert, Dividende, Schweizer, Aktienmarkt, Vergleich, Ausnahme, Vorzeichen, FDA, Arzneimittel, Experte, Investment, Management, Team, Branche, Impulse, Ergebnis, Studie, Portfolio, Anfang, Meilenstein, Vertex, Behandlung, Schmerz, Programm, Erfolg, Quartal, Bedeutung, Beteiligung, Klinische Studie, Therapie, Depression, Bewertung

EQS-News: BB Biotech AG: Jahresendrally des Biotechsektors durch M&A-Aktivitäten und Zinswende beflügelt

Retrieved on: 
Martedì, Gennaio 30, 2024
Portfolio, BB, Trotz, Aufschwung, Aktie, Geschäftsjahr, CHF, USD, Prime, Verwaltungsrat, Generalversammlung, Rendite, Maßnahme, Zentralbank, Schweizer, Bedeutung, Dividende, Quartal, NAV, Abwertung, Doktor, Wahl, Weitblick, Governance, Investment, Management, Team, Positionen, Sektor, Inkrementalgeber, Ergebnis, Studie, Verbindung, Kapitalmarkt, Unternehmen, Beschaffung, Betriebsnotwendiges Vermögen, Ansicht, Microsoft Teams, Marke (Recht), Suche, Investition, System, Gesundheitssystem

EQS-News: BB Biotech AG: End of year biotech equity market rally – M&A and end of rate hike cycle

Retrieved on: 
Martedì, Gennaio 30, 2024
Neuroscience, Patient, Annual general meeting, United States dollar, Research, ADC, Health care, Policy, Biotechnology, NAV, Dax, Intelligence, Annual, SGA, BB Biotech, AGM, Euro, Investment, Hereditary angioedema, EQT, Consolidated, Lifting, Hunziker, CHF, Affibody molecule, Thalassemia, Annual report, Clinical trial, MSCI, Cardiomyopathy, Revolution, Pharmaceutical industry

Media release as at January 19, 2024

Key Points: 
  • Media release as at January 19, 2024
    Portfolio of BB Biotech AG as at December 31, 2023
    In 2023, global equity performed better than anticipated by many.
  • Consequently, BB Biotech ended the year with a net loss of CHF 207 mn.
  • This represents a 5% return based on the volume-weighted average closing price of BB Biotech shares in December 2023.
  • The US central bank held rates steady in the fall, lifting market sentiment in the last two months of 2023.

EQS-News: BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies

Retrieved on: 
Giovedì, Ottobre 26, 2023
Neoplasm, FDA, Federal Trade Commission, HHS, Attention, Chronic inflammatory demyelinating polyneuropathy, Ovarian cancer, Frankfurt Stock Exchange, NASDAQ Biotechnology Index, Government, Obesity, Fundamental, DSM-IV codes, Alnylam Pharmaceuticals, CAH, Neurocrine, Posture, SIX Swiss Exchange, Office of Inspector General, U.S. Department of Health and Human Services, Zuranolone, Congenital adrenal hyperplasia, Biotechnology, Inflation Reduction Act of 2022, Hypertension, NBI, Amgen, NET, Depression, BB Biotech, Platinum, NAV, CIDP, Woman, FTC, Inflation, Investment, Therapy, Patient, Cabozantinib, CHF, POC, Security (finance), Rare-earth element, Public utility, Pharmaceutical industry, Bank, Vertex, Incyte, EUR, USD, Valbenazine

BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies

Key Points: 
  • BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies
    The issuer is solely responsible for the content of this announcement.
  • The rise in bond yields weighed heavily on biotech stocks as well as the stock market in general.
  • BB Biotech benefited from the dollar's appreciation, but it was also exposed to the sustained selling pressure on equity markets.
  • BB Biotech traded within a narrow range during the third quarter, closing slightly higher at CHF 41.35 per share.